The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma.
 
Elizabeth J. Hovey
Consulting or Advisory Role - Bayer; Janssen Oncology; Pfizer; Roche Pharma AG
Travel, Accommodations, Expenses - GlaxoSmithKline; Sanofi
 
Kathryn Maree Field
Speakers' Bureau - Roche Pharma AG
Research Funding - Roche Pharma AG
 
Mark Rosenthal
No Relationships to Disclose
 
Anna K. Nowak
Consulting or Advisory Role - Boehringer Ingelheim; Roche Pharma AG
Research Funding - Boehringer Ingelheim (Inst)
 
Lawrence Cher
Honoraria - Roche Pharma AG
Consulting or Advisory Role - Roche Pharma AG
Research Funding - Celldex (Inst); Lilly (Inst); Merck (Inst); Roche Pharma AG (Inst)
 
Helen Wheeler
No Relationships to Disclose
 
Elizabeth Barnes
No Relationships to Disclose
 
Pramit Phal
No Relationships to Disclose
 
Ann Livingstone
No Relationships to Disclose
 
Kate Sawkins
Research Funding - Roche Pharma AG (Inst)
 
John Simes
Research Funding - Roche Pharma AG (Inst)